Clinical trials of therapy with fibric
|
|
- Verity Madlyn Briggs
- 8 years ago
- Views:
Transcription
1 Pathophysiology/Complications O R I G I N A L A R T I C L E Beneficial Effects of Fenofibrate to Improve Endothelial Dysfunction and Raise Adiponectin Levels in Patients With Primary Hypertriglyceridemia KWANG KON KOH, MD, PHD, FACC, FAHA 1 SEUNG HWAN HAN, MD 1 MICHAEL J. QUON, MD, PHD 3 2 JEONG YEAL AHN, MD EAK KYUN SHIN, MD 1 OBJECTIVE Improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease. We hypothesize fenofibrate improves endothelial function by enhancing insulin sensitivity. RESEARCH DESIGN AND METHODS We administered placebo or fenofibrate 200 mg daily for 8 weeks to 46 patients with primary hypertriglyceridemia (24 had metabolic syndrome). This study was randomized, double blind, placebo controlled, and crossover in design. RESULTS Compared with placebo, fenofibrate decreased total cholesterol, non-hdl cholesterol, apolipoprotein B, and triglycerides and increased HDL cholesterol and apolipoprotein A-I (all P 0.001) while tending to decrease LDL cholesterol (P 0.069). Fenofibrate significantly improved percent flow-mediated dilator response to hyperemia by 48 5% (P 0.001) and lowered plasma levels of high-sensitivity C-reactive protein (hscrp) relative to baseline measurements from 0.80 to 0.70 mg/l (P 0.001) and fibrinogen levels by 16 3% (P 0.001). Compared with placebo, fenofibrate therapy significantly increased plasma levels of adiponectin by 14 5% (P 0.008) and increased insulin sensitivity (assessed by quantitative insulin sensitivity check index [QUICKI]) by 6 2% (P 0.048). There were significant correlations between percent changes in adiponectin levels and percent changes in flowmediated dilation (r 0.401, P 0.006), hscrp (r 0.443, P 0.002), or QUICKI (r 0.292, P 0.049). Multivariate regression analysis showed that only changes in adiponectin levels persisted as an independent predictor of changes in flow-mediated dilation (r 0.504, P 0.013). Overall, we observed similar results in 24 patients with metabolic syndrome. CONCLUSIONS Fenofibrate therapy significantly improved percent flow-mediated dilator response to hyperemia, reduced inflammation marker levels, increased adiponectin levels, and improved insulin sensitivity in hypertriglyceridemic or metabolic syndrome patients. Diabetes Care 28: , 2005 From the 1 Division of Cardiology, Gachon Medical School, Incheon, Korea; the 2 Division of Laboratory Medicine, Gachon Medical School, Incheon, Korea; and the 3 Diabetes Unit, Laboratory of Clinical Investigation, National Center for Complementary and Alternative Medicine, National Institutes of Health, Bethesda, Maryland. Address correspondence and reprint requests to Kwang Kon Koh, MD, PhD, FACC, FAHA, Professor of Medicine, Director, Vascular Medicine and Atherosclerosis Unit, Division of Cardiology, Gil Heart Center, Gachon Medical School, 1198 Kuwol-dong, Namdong-gu, Incheon, Korea kwangk@ghil. com. Received for publication 9 December 2004 and accepted in revised form 16 February Abbreviations: hscrp, high-sensitivity C-reactive protein; PPAR, peroxisome proliferator activated receptor; QUICKI, quantitative insulin sensitivity check index. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances by the American Diabetes Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Clinical trials of therapy with fibric acid derivatives demonstrate an improvement in cardiovascular end points and coronary stenosis (1). Peroxisome proliferator activated receptors (PPARs) are nuclear receptors activated by fatty acids and derivatives. PPAR mediates the hypolipidemic action of fibrates and is highly expressed in tissues such as heart, where it stimulates the -oxidative degradation of fatty acids. PPAR controls plasma levels of cholesterol and triglycerides, which constitute major risk factors for coronary heart disease. Furthermore, experimental studies have shown that PPAR regulates the expression of key proteins involved in all stages of atherogenesis such as vascular inflammation, suggesting that PPAR exerts direct antiatherogenic actions at the level of the vascular wall (2). These direct vascular effects of fibrates may contribute to the cardiovascular event reduction and explain the clinical benefit in these clinical trials. The endothelial dysfunction associated with metabolic syndrome and other insulin-resistant states are characterized by impaired nitric oxide (NO) release from endothelium (3). Thus, improvement in endothelial function is predicted to improve insulin sensitivity, and this may be one mechanism by which fenofibrate decreases the incidence of coronary heart disease. Excess body fat is frequently associated with dyslipidemia, metabolic syndrome, and atherosclerotic vascular diseases (4). Adiponectin is one of a number of proteins secreted by adipose cells that may couple regulation of insulin sensitivity with energy metabolism and serve to link obesity with insulin resistance (5). Decreased plasma adiponectin levels are observed in patients with diabetes and patients with coronary artery disease (4). Thus, decreased levels of adiponectin may also play a key role in the development of insulin resistance. In addition, adiponectin also possesses DIABETES CARE, VOLUME 28, NUMBER 6, JUNE
2 Metabolic effects of fenofibrate antiatherogenic properties. For example, adiponectin stimulates production of NO (6). However, to date, there are no published studies that have investigated the effects of fenofibrate on adiponectin and insulin sensitivity in patients with hypertriglyceridemia. Therefore, we investigated the vascular and metabolic effects of fenofibrate in patients with hypertriglyceridemia. RESEARCH DESIGN AND METHODS This study was randomized, double blind, placebo controlled, and crossover in design. None had diabetes, were smokers, or had previous angina. We excluded patients with moderate or severe hypertension, nephrotic syndrome, hypothyroidism, coronary artery disease, or peripheral vascular disease. No patient had taken any cholesterol-lowering agent, hormone replacement therapy, or antioxidant vitamin supplements during the preceding 2 months. We administered placebo or micronized fenofibrate 200 mg daily to 46 patients with primary hypertriglyceridemia ( 150 mg/dl) for 8 weeks, with the second treatment period initiated upon completion of the first treatment period (without washout phase). A research nurse counted pills at the end of treatment to monitor compliance. Baseline total cholesterol, triglyceride, LDL cholesterol, HDL cholesterol, non-hdl cholesterol, apolipoprotein B, and apolipoprotein A-I levels were 236 8, , 133 8, 44 1, 192 7, 132 4, and mg/dl, respectively. The mean age was 57 1 years, and 18 (39%) were men. Mean BMI was kg/m 2. Ten of 46 patients were mildly hypertensive. No additional medications, including antihypertensive drugs, aspirin, or nonsteroidal antiinflammatory drugs, were allowed during the study period to avoid other drugs effects. Twenty-four of 46 patients had metabolic syndrome according to the definition of National Cholesterol Education Program Adult Treatment Panel III (7). The study was approved by the Gil Hospital Institute Review Board, and all participants gave written informed consent. Laboratory assays Blood samples for laboratory assays were obtained at 8:00 A.M. following an overnight fast before and at the end of each treatment period. Placebo or fenofibrate was taken at 7:00 P.M. following meals. These samples were immediately coded so that investigators performing laboratory assays were blinded to subject identity or study sequence. Assays for lipids, glucose, and plasma adiponectin were performed in duplicate by enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, MN) and assays for highsensitivity C-reactive protein (hscrp) levels by latex agglutination (CRP-Latex (II); Denka-Seiken, Tokyo, Japan). Assays for plasma insulin levels were performed in duplicate by immunoradiometric assay (Insulin-Riabead II; Abbott Japan, Tokyo, Japan). All samples from the same patient (batch samples) were measured in blinded pairs on the same enzyme-linked immunosorbent assay kit to minimize run-to-run variability. The interassay and intra-assay coefficients of variation (CVs) were 6%. Quantitative insulin sensitivity check index (QUICKI), a surrogate index of insulin sensitivity, was calculated as follows (insulin is expressed in U/ml and glucose in mg/dl): QUICKI 1/[log- (insulin) log(glucose)] (8). Vascular studies Imaging studies of the right brachial artery were performed using an ATL HDI 3000 ultrasound machine (Bothell, WA) equipped with a 10-MHz linear-array transducer and lower-arm occlusion technique, based on a previously published technique (9,10). All images were transmitted to a personal computer via ethernet with DICOM (digital imaging and communication in medicine) format and then saved on the hard disk of a personal computer in bitmap format. Arterial diameters were measured with Image Tool for Windows version 2.0 (University of Texas Health Science Center, San Antonio, TX). Measurements were performed by investigators blinded to the subject s identity and medication status. Measurements of maximum diameter and percent flow-mediated dilation were made in 10 studies selected at random. The inter- and intraobserver variability for repeated measurement of maximum diameter were and mm, respectively. The inter- and intraobserver variability for repeated measurement of percent flow-mediated dilation were and %, respectively. Statistical analysis Data are expressed as means SE or median (range 25 75%). After testing data for normality, we used Student s paired t or Wilcoxon signed rank test to compare the relative changes in values in response to placebo and fenofibrate treatments, as reported in Tables 1 and 2. We did not incorporate a washout period between placebo and fenofibrate treatments based on our previous study (9). However, to assess the possibility of a carryover effect from the initial treatment periods to the next treatment period, we compared the percent changes of 1) the first treatment placebo and the second treatment placebo with 2) the first treatment fenofibrate and the second treatment fenofibrate relative to baseline values by using Student s unpaired t or Mann-Whitney rank sum test. No significant differences were found in the above two comparisons. In other words, there were no detectable carryover effects. Pearson or Spearman correlation coefficient analysis was used to assess associations between measured parameters. We calculated that 30 subjects would provide 80% power for detecting an absolute increase of 1.5% in flowmediated dilation of the brachial artery between placebo and fenofibrate, with 0.05 based on our previous studies (9 11). The comparison of endotheliumdependent dilation between placebo and fenofibrate was prospectively designated as the primary end point of the study. All other comparisons were considered secondary. A value of P 0.05 was considered to be statistically significant. RESULTS Effects of therapies on lipids and vasomotor function There were no significant differences in BMI between placebo and fenofibrate, and BMI was unchanged by either therapy. Compared with placebo, fenofibrate significantly changed lipoprotein levels. As expected, fenofibrate decreased total cholesterol, non-hdl cholesterol, apolipoprotein B, and triglycerides and increased HDL cholesterol and apolipoprotein A-I (all P 0.001; Table 1) and tended to decrease LDL cholesterol (P 0.069). Fenofibrate significantly im DIABETES CARE, VOLUME 28, NUMBER 6, JUNE 2005
3 Koh and Associates Table 1 Effects of fenofibrate in 46 hypertryglyceridemic patients Variables Placebo Fenofibrate Percent changes BMI (kg/m 2 ) (2.75) (2.75) Lipids (mg/dl) Total cholesterol (50) (35)* 11 2 (15)* Triglycerides (105) (59)* 47 4 (28)* LDL cholesterol (52) (34) 1 6 (39) Apolipoprotein B (28) (22)* 21 3 (18)* HDL cholesterol 45 1 (9) 55 2 (12)* 25 4 (24)* Apolipoprotein A-I (20) (28)* 9 2 (13)* Non-HDL cholesterol (48) (36)* 19 3 (18)* Vasomotor function Brachial artery diameter (mm) Basal (0.45) (0.42) 0 1 (7) Hyperemia (0.46) (0.45) 2 1 (7) Basal (0.45) (0.44) 0 1 (8) Nitroglycerin (0.50) (0.50) 2 1 (7) Flow-mediated dilation (%) (1.30) (1.29)* 48 5 (34)* Nitroglycerin dilation (%) (3.05) (3.57) 7 3 (23) Fibrinogen (mg/dl) (72) (61)* 16 3 (21)* CRP (mg/l) 0.80 ( ) 0.70 ( )* (233)* Insulin resistance ADP ( g/ml) 3.21 ( ) 3.54 ( ) 14 5 (37) Insulin ( U/ml) (2.24) (2.99) 1 11 (75) Glucose (mg/dl) 89 4 (26) 88 3 (23) 1 3 (19) QUICKI (0.072) (0.069) 6 2 (14) Data are means SE (SD) or median (25th 75th percentile). *P vs. placebo, P 0.01, P After testing data for normality, we used Student s paired t or Wilcoxon signed rank test to compare the relative changes in values in response to placebo and fenofibrate treatments. Non-HDL cholesterol total cholesterol HDL cholesterol. QUICKI 1/ log(insulin) log(glucose) (8). proved the percent flow-mediated dilator response to hyperemia by 48 5% (P 0.001; Fig. 1, Table 1). However, the brachial artery dilator response to nitroglycerin was not significantly changed (P 0.169). Of interest, there was a siginificant inverse correlation between the flowmediated dilation following placebo and the percent change in flow-mediated dilation following fenofibrate (r 0.745, P ). Following fenofibrate therapy, improvement in flow-mediated dilation inversely correlated with changes in total cholesterol levels (r and P 0.029), LDL cholesterol levels (r and P 0.041), and non-hdl cholesterol levels (r 0.389, P 0.008). However, changes in flow-mediated dilation were not significantly correlated with changes in triglyceride levels (r and P 0.229) and HDL cholesterol levels (r 0.244, P 0.102). Effects of therapies on adiponectin and insulin resistance There were inverse correlations between BMI and baseline plasma adiponectin levels (r 0.283, P 0.057). There were significant correlations between baseline adiponectin levels and baseline triglycerides (r 0.331, P 0.025), HDL cholesterol (r 0.339, P 0.021), insulin (r 0.337, P 0.022), or QUICKI (r 0.391, P 0.007). Compared with placebo, fenofibrate therapy significantly increased plasma levels of adiponectin by 14 5% (P 0.008; Fig. 1). Fenofibrate therapy did not significantly change fasting insulin and glucose levels. However, compared with placebo, fenofibrate therapy significantly increased QUICKI by 6 2% (P 0.048). There were correlations between percent changes in adiponectin levels and percent changes in flow-mediated dilation (r 0.401, P 0.006), hscrp (r 0.443, P 0.002), QUICKI (r 0.292, P 0.049), or insulin (r 0.273, P 0.067). The relationship between changes in flow-mediated dilation and changes in adiponectin levels was also investigated in a multivariate setting with other predictors (glucose, HDL cholesterol, triglycerides, and BMI). Only changes in adiponectin levels persisted as an independent predictor of changes in flow-mediated dilation (r 0.504, P 0.013). Effects of therapies on hscrp and fibrinogen Compared with placebo, fenofibrate significantly lowered plasma levels of hscrp from 0.80 to 0.70 mg/l (P 0.001) and fibrinogen levels by 16 3% (P 0.001). Effects of therapies in patients with metabolic syndrome We analyzed 24 patients with metabolic syndrome, as reported in Table 2. Overall, compared with the effects of fenofibrate in 46 hypertriglyceridemic patients, we observed similar results in 24 patients with metabolic syndrome. Compared with placebo, fenofibrate significantly changed lipoprotein and fibrinogen levels and significantly improved the percent flowmediated dilator response to hyperemia by 47 6% (P 0.001; Table 2). Compared with placebo, fenofibrate therapy significantly increased plasma levels of adiponectin by 12 6% (P 0.021). Fenofibrate therapy did not significantly change fasting insulin and glucose levels. DIABETES CARE, VOLUME 28, NUMBER 6, JUNE
4 Metabolic effects of fenofibrate Table 2 Effects of fenofibrate in 24 patients with metabolic syndrome among 46 hypertryglyceridemic patients Variables Placebo Fenofibrate Percent changes Age (years) 58 2 (42 74) Sex (men:women) 10:14 BMI (kg/m 2 ) (2.84) (2.82) Lipids (mg/dl) Total cholesterol (42) (35) 5 3 (16) Triglycerides (90) (59)* 51 5 (24)* LDL cholesterol (43) (30) 20 9 (44) Apolipoprotein B (25) (20)* 12 4 (21)* HDL cholesterol 42 2 (9) 52 3 (13)* 24 5 (23)* Apolipoprotein A-I (21) (31) 9 3 (14) Non-HDL cholesterol (37) (31) 12 4 (19) Vasomotor function Brachial artery diameter (mm) Basal (0.47) (0.34) 1 2 (9) Hyperemia (0.48) (0.37) 2 2 (9) Basal (0.47) (0.39) 1 2 (10) Nitroglycerin (0.49) (0.46) 2 2 (9) Flow-mediated dilation (%) (1.42) (1.44)* 47 6 (31)* Nitroglycerin dilation (%) (3.36) (3.07) 5 5 (24) Fibrinogen (mg/dl) (51) (56)* 17 3 (16)* CRP (mg/l) 0.75 ( ) 0.80 ( ) (314) Insulin resistance ADP ( g/ml) 3.35 ( ) 3.55 ( ) 12 6 (30) Insulin ( U/ml) (2.44) (3.47) (51) Glucose (mg/dl) 95 7 (32) 95 6 (28) 2 3 (17) QUICKI (0.057) (0.072) 6 3 (13) Data are expressed as means SE (SD) or median (25th 75th percentile). *P 0.001, P 0.01, P 0.05 vs. placebo. After testing data for normality, we used Student s paired t or Wilcoxon signed rank test to compare the relative changes in values in response to placebo and fenofibrate treatments. Non-HDL cholesterol total cholesterol HDL cholesterol. QUICKI 1/ log(insulin) log(glucose) (8). However, compared with placebo, fenofibrate therapy significantly increased QUICKI by 6 3% (P 0.026). Fenofibrate therapy did not significantly reduce hscrp levels (P 0.092). CONCLUSIONS We observed that fenofibrate therapy significantly improved the percent flow-mediated dilator response to hyperemia, reduced levels of inflammation markers, increased adiponectin levels, and improved insulin sensitivity in hypertriglyceridemic patients. Several studies (12,13) have examined the effect of fibrates on vasomotor function. In the current study, we observed that fenofibrate significantly improved the percent flow-mediated dilator response to hyperemia consistent with other studies (12,13). Plausible mechanisms underlying improvement of flowmediated dilation following fenofibrate include changes of lipoproteins. In support of this speculation, we observed significant correlations between the improvement in flow-mediated dilation and the changes in total cholesterol, LDL cholesterol, and non-hdl cholesterol levels. Niacin treatment increases HDL cholesterol levels, improves flow-mediated dilation, and increases endothelial NO synthase expression in patients, suggesting that HDL-mediated increases in endothelial NO synthase expression and activity may contribute to the observed enhancement in vasorelaxation (14). In the current study, we observed that fenofibrate treatment increased HDL cholesterol levels and improved flow-mediated dilation; however, we did not observe a significant correlation between the improvement in flow-mediated dilation and the changes in HDL cholesterol. We also observed that fenofibrate therapy caused a small, but statistically significant, decrease in hscrp levels, consistent with the findings of others (12). When evaluating the physiological relevance of this finding, it may be important to consider that our subjects were patients with primary hypertriglyceridemia without coronary artery disease or other risk factors who had relatively low pretreatment hscrp levels (median 0.8 mg/l), and, thus, the reduction of absolute levels of hscrp by fenofibrate, while statistically significant, is small. Moreover, it is important to note that in our study, multiple independent markers (including triglyceride levels, adiponectin levels, and QUICKI) all changed in a manner that is consistent with improved insulin sensitivity. This reinforces and supports our hypothesis that these factors are linked by pathophysiological mechanisms. Nevertheless, conclusive demonstration of the clinical relevance of these small, but statistically significant, changes will require a prospectively designed large-scale clinical trial that is beyond the scope of the present study. Fenofibrate therapy resulted in significant elevation of adiponectin levels and increased insulin sensitivity (assessed by QUICKI). QUICKI is a reliable surrogate index for insulin sensitivity that has an especially excellent correlation with the reference standard glucose clamp method 1422 DIABETES CARE, VOLUME 28, NUMBER 6, JUNE 2005
5 Koh and Associates Figure 1 Compared with placebo, fenofibrate significantly improved the percent flow-mediated dilator response to hyperemia (A) and increased plasma levels of adiponectin (B). Mean values are identified by open circles. in insulin-resistant subjects with type 2 diabetes or obesity (r 0.9 in subjects with these diseases) (8). In addition, test characteristics of QUICKI including CV (CV 0.05) and discriminant ratio are significantly better than other simple surrogate indexes and comparable with those of the glucose clamp (15). In a number of relevant clinical conditions, including type 2 diabetes, gestational diabetes, and hypertension, QUICKI can appropriately follow changes in insulin sensitivity after various therapeutic interventions when compared directly with glucose clamp results (15,16). Moreover, a large meta-analysis of insulin-resistant subjects demonstrated that QUICKI is among the best surrogate indexes in terms of predictive power for the onset of diabetes (17). Of particular relevance to this study, decreasing values for QUICKI are also a reliable predictor of increased carotid intima-media thickness (18). Since changes in insulin sensitivity were a secondary outcome for this study, our data on improved insulin sensitivity should be regarded as pilot data for a more focused study on insulin sensitivity. The present study is the first report demonstrating that fenofibrate therapy increases adiponectin levels. Adiponectin is an adipose-derived factor that augments and mimics metabolic actions of insulin. Adiponectin can directly stimulate NO production from endothelium via activation of AMP-activated protein kinase (6). Therefore, increasing adiponectin levels would be predicted to improve both insulin sensitivity and endothelial function by multiple mechanisms. Regulation of metabolic homeostasis and hemodynamic homeostasis may be coupled by vascular actions of insulin to stimulate production of NO (6). Thus, improvements in endothelial function may increase insulin sensitivity, while increased insulin sensitivity may improve endothelial function (3). On the other hand, there may be additional mechanisms for fenofibrate therapy to improve insulin sensitivity that are independent of endothelial function. PPAR activators improve insulin sensitivity and reduce adiposity in rodent models (19). Effects of fenofibrate therapy to increase adiponectin levels may mediate, in part, improved insulin sensitivity supported by significant correlations shown in the present study. Fenofibrate therapy for 2 months treatment increased adiponectin levels without a change in body weight. This raises the possibility that drug therapy is directly altering adiponectin levels independent of adiposity. Thus, it is possible that increased adiponectin levels are contributing to improvement in insulin sensitivity rather than simply reflecting a change in adiposity. Metabolic syndrome is associated with atherosclerotic disease. Obesity is one of the most important contributors to cardiovascular disease. Adipose tissue secretes various bioactive molecules that may directly contribute to the development of obesity-related diseases (20). Dysregulation of adipocyte-derived endocrine factors caused by overnutrition may directly participate in the development of atherosclerosis. Adiponectin may couple regulation of insulin sensitivity with energy metabolism, serve to link obesity with insulin resistance, and possess antiatherogenic properties. In the present study, more than half (57%) of subjects were overweight. Furthermore, compared with the effects of fenofibrate in 46 hypertriglyceridemic patients, we observed similar results in a subgroup of 24 patients with the metabolic syndrome. Thus, our study has implications for the treatment of patients with the metabolic syndrome. Of interest, we observed significant correlations between the degree of changes in adiponectin levels and flow-mediated dilation, insulin levels, QUICKI, or hscrp levels following fenofibrate therapy. Thus, our findings are consistent with those of Ouchi et al. (21), who demonstrated that plasma hscrp levels were negatively correlated with plasma adiponectin levels in male coronary artery disease patients. Our multivariate regression analysis demonstrated that only changes in adiponectin levels persisted as an independent predictor of changes in flowmediated dilation (r 0.504, P 0.013). In conclusion, fenofibrate therapy significantly improved percent flowmediated dilator response to hyperemia, reduced levels of inflammation markers, increased adiponectin levels, and improved insulin sensitivity in hypertriglyceridemic patients with or without metabolic syndrome. The effects of fenofibrate treatment to improve endothelial function and insulin sensitivity and to suppress inflammatory markers relevant to cardiovascular disease are likely to have important beneficial health consequences in patients with hypertriglyceridemia or the metabolic syndrome. Acknowledgments We greatly appreciate the critical review and comments of Myron A. Waclawiw, PhD (Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Rockville, MD). We will present our study in part as abstracts in the 54th Annual Scientific Session of the American College of DIABETES CARE, VOLUME 28, NUMBER 6, JUNE
6 Metabolic effects of fenofibrate Cardiology, Orlando, Florida, 6 9 March References 1. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High- Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341: , Barbier O, Torra IP, Duguay Y, Blanquart C, Fruchart JC, Glineur C, Staels B: Pleiotropic actions of peroxisome proliferatoractivated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22: , Vincent MA, Montagnani M, Quon MJ: Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 3: , Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Funahashi T, Matsuzawa Y, the Osaka CAD Study Group: Coronary artery disease: association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 23: 85 89, Heilbronn LK, Smith SR, Ravussin E: The insulin-sensitizing role of the fat derived hormone adiponectin. Curr Pharm Des 9: , Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ: Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 278: , National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: , Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ: Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85: , Koh KK, Ahn JY, Han SH, Kim DS, Jin DK, Kim HS, Shin MS, Ahn TH, Choi IS, Shin EK: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 42: , Koh KK, Quon MJ, Han SH, Chung W-J, Ahn JY, Seo Y-H, Kang MH, Ahn TH, Choi IS, Shin EK: Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110: , Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, Kim DS, Jeong EM, Park GS, Choi IS, Shin EK: Comparative effects of diet and statin on nitric oxide bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22:E19 E23, Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A: Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 101: , Marchesi S, Lupattelli G, Lombardini R, Roscini AR, Siepi D, Vaudo G, Pirro M, Sinzinger H, Schillaci G, Mannarino E: Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia. J Clin Pharm Ther 28: , Kuvin JT, Ramet ME, Patel AR, Pandian NG, Mendelsohn ME, Karas RH: A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 144: , Mather KJ, Hunt AE, Steinberg HO, Paradisi G, Hook G, Katz A, Quon MJ, Baron AD: Repeatability characteristics of simple indices of insulin resistance: implications for research applications. J Clin Endocrinol Metab 86: , Katsuki A, Sumida Y, Gabazza EC, Murashima S, Urakawa H, Morioka K, Kitagawa N, Tanaka T, Araki-Sasaki R, Hori Y, Nakatani K, Yano Y, Adachi Y: QUICKI is useful for following improvements in insulin sensitivity after therapy in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 87: , Hanley AJ, Williams K, Gonzalez C, D Agostino RB Jr, Wagenknecht LE, Stern MP, Haffner SM, the San Antonio Heart Study, the Mexico City Diabetes Study, the Insulin Resistance Atherosclerosis Study: Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 52: , Rajala U, Laakso M, Paivansalo M, Pelkonen O, Suramo I, Keinanen-Kiukaanniemi S: Low insulin sensitivity measured by both quantitative insulin sensitivity check index and homeostasis model assessment method as a risk factor of increased intima-media thickness of the carotid artery. J Clin Endocrinol Metab 87: , Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: , Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259:87 91, Ouchi N, Kihara S, Funahashi T, Nakamura T, Nishida M, Kumada M, Okamoto Y, Ohashi K, Nagaretani H, Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y: Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue. Circulation 107: , DIABETES CARE, VOLUME 28, NUMBER 6, JUNE 2005
Role of Body Weight Reduction in Obesity-Associated Co-Morbidities
Obesity Role of Body Weight Reduction in JMAJ 48(1): 47 1, 2 Hideaki BUJO Professor, Department of Genome Research and Clinical Application (M6) Graduate School of Medicine, Chiba University Abstract:
More informationYour Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007
Your Life Your Health Cariodmetabolic Risk Syndrome Part VII Inflammation chronic, low-grade By James L. Holly, MD The Examiner January 25, 2007 The cardiometabolic risk syndrome is increasingly recognized
More informationRobert Krysiak, Anna Gdula-Dymek, Bogus³aw Okopieñ
Pharmacological Reports 2013, 65, 429 434 ISSN 1734-1140 Copyright 2013 by Institute of Pharmacology Polish Academy of Sciences Lymphocyte-suppressing, endothelial-protective and systemic anti-inflammatory
More informationEducation. Panel. Triglycerides & HDL-C
Triglycerides & HDL-C Thomas Dayspring, MD, ACP Clinical Assistant Professor of Medicine University of Medicine and Dentistry of New Jersey Attending in Medicine: St Joseph s s Hospital, Paterson, NJ Certified
More informationHigh Blood Cholesterol
National Cholesterol Education Program ATP III Guidelines At-A-Glance Quick Desk Reference 1 Step 1 2 Step 2 3 Step 3 Determine lipoprotein levels obtain complete lipoprotein profile after 9- to 12-hour
More informationVascular Effects of Caffeine
Vascular Effects of Caffeine John P. Higgins MD, MBA, MPHIL, FACC, FACP, FAHA, FACSM, FASNC, FSGC Director of Exercise Physiology Memorial Hermann Sports Medicine Institute Chief of Cardiology, Lyndon
More informationROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE
ROLE OF LDL CHOLESTEROL, HDL CHOLESTEROL AND TRIGLYCERIDES IN THE PREVENTION OF CORONARY HEART DISEASE AND STROKE I- BACKGROUND: Coronary artery disease and stoke are the major killers in the United States.
More informationFreiburg Study. The other 24 subjects had healthy markers closer to what would be considered ideal.
Freiburg Study The Freiburg Study was conducted with 48 healthy human subjects of various ages. None of the test subjects had been diagnosed with any disease prior to the study. None were taking any type
More informationLDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts.
LDL PARTICLE SIZE: DOES IT MATTER? Samia Mora, M.D., M.H.S., Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts Introduction While both small and large LDL particles may be atherogenic,
More informationHow To Treat Dyslipidemia
An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia Introduction Executive Summary The International Atherosclerosis Society (IAS) here updates
More informationInitiation and Adjustment of Insulin Regimens
Start with bedtime intermediateacting insulin or bedtime or morning long-acting insulin (can initiate with 10 units or 0.2 units per kg) Initiation and Adjustment of Insulin Regimens Insulin regimens should
More informationMetabolic Syndrome Overview: Easy Living, Bitter Harvest. Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007
Metabolic Syndrome Overview: Easy Living, Bitter Harvest Sabrina Gill MD MPH FRCPC Caroline Stigant MD FRCPC BC Nephrology Days, October 2007 Evolution of Metabolic Syndrome 1923: Kylin describes clustering
More informationCardiovascular disease physiology. Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011
Cardiovascular disease physiology Linda Lowe-Krentz Bioscience in the 21 st Century October 14, 2011 Content Introduction The number 1 killer in America Some statistics Recommendations The disease process
More informationMANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF LIPID DISORDERS: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING
More informationIntroduction. Pathogenesis of type 2 diabetes
Introduction Type 2 diabetes mellitus (t2dm) is the most prevalent form of diabetes worldwide. It is characterised by high fasting and high postprandial blood glucose concentrations (hyperglycemia). Chronic
More informationStatin Therapy on Insulin Resistance and Plasma Level of Adiponectin in Non-Diabetic, Hypercholesterolemic Patients
Original Article??? Acta Cardiol Sin 2009;25:183 9 Statin Therapy Statin Therapy on Insulin Resistance and Plasma Level of Adiponectin in Non-Diabetic, Hypercholesterolemic Patients Philip Yu-An Ding,
More informationDiabetes and Obesity. The diabesity epidemic
Diabetes and Obesity Frank B. Diamond, Jr. M.D. Professor of Pediatrics University of South Florida College of Medicine The diabesity epidemic Prevalence of diabetes worldwide was over 135 million people
More informationDIABETES AND INSULIN RESISTANCE DIABETES PREVALANCE
DIABETES AND INSULIN RESISTANCE KARI KOHRS RD LDN CDE UICMC NUTRITION & WELLNESS CENTER DIABETES PREVALANCE Third leading cause of death-- United States 18 million diagnosed Growing at the rate of 3 new
More informationHDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism
HDL Cholesterol Subfractions and the Effect of Testosterone Replacement in Hypogonadism E. Bolu 1, A. Sonmez 1, S. Tapan 2, A. Taslipinar 1, A. Aydogdu 1, C. Meric 1, Y. Basaran 1, G. Uckaya 1, M. Serdar
More informationBody Composition & Longevity. Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ
Body Composition & Longevity Ohan Karatoprak, MD, AAFP Clinical Assistant Professor, UMDNJ LONGEVITY Genetic 25% Environmental Lifestyle Stress 75% BMI >30 OBESE 25-30 OVERWEIGHT 18-25 NORMAL WEIGHT 18
More informationAnti-Atheroscrerotic Drugs
Anti-Atheroscrerotic Drugs Masuko Ushio-Fukai, PhD, FAHA Dept. of Pharmacology University of Illinois at Chicago Anti-Atherogenic Drugs: Treatment of Hyperlipidemias Knowledge Objectives: 1) Know the mechanism
More informationProtein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075
Title: Protein Intake in Potentially Insulin Resistant Adults: Impact on Glycemic and Lipoprotein Profiles - NPB #01-075 Investigator: Institution: Gail Gates, PhD, RD/LD Oklahoma State University Date
More informationGetting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research?
Getting Off the Chronic Disease Merry-Go-Round: What s the Weight of the Research? Jody Dushay, MD MMSc Beth Israel Deaconess Medical Center Boston, MA Session 445 No disclosures Disclosure Jody Dushay,
More informationRisk Factors for Fire Fighter Cardiovascular Disease
Risk Factors for Fire Fighter Cardiovascular Disease EXECUTIVE SUMMARY Prepared by: Jefferey L. Burgess, MD, MS, MPH Mel and Enid Zuckerman College of Public Health The University of Arizona The Fire Protection
More informationImproving cardiometabolic health in Major Mental Illness
Improving cardiometabolic health in Major Mental Illness Dr. Adrian Heald Consultant in Endocrinology and Diabetes Leighton Hospital, Crewe and Macclesfield Research Fellow, Manchester University Metabolic
More informationMain Effect of Screening for Coronary Artery Disease Using CT
Main Effect of Screening for Coronary Artery Disease Using CT Angiography on Mortality and Cardiac Events in High risk Patients with Diabetes: The FACTOR-64 Randomized Clinical Trial Joseph B. Muhlestein,
More informationSubject Index. Bariatric surgery, obesity management 134
Subject Index Acromegaly, PCOS differential diagnosis 149, 150, 154, 155 Adipokines, see specific adipokines Adiponectin, metabolic syndrome role 41 43 Adolescents, PCOS diagnosis 16, 17 Adrenal hyperplasia,
More informationJournal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators
Journal Club: Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy by the AIM-HIGH Investigators Shaikha Al Naimi Doctor of Pharmacy Student College of Pharmacy Qatar University
More information4/4/2013. Mike Rizo, Pharm D, MBA, ABAAHP THE PHARMACIST OF THE FUTURE? METABOLIC SYNDROME AN INTEGRATIVE APPROACH
METABOLIC SYNDROME AN INTEGRATIVE APPROACH AN OPPORTUNITY FOR PHARMACISTS TO MAKE A DIFFERENCE Mike Rizo, Pharm D, MBA, ABAAHP THE EVOLUTION OF THE PHARMACIST 1920s 1960s 2000s THE PHARMACIST OF THE FUTURE?
More informationObesity in the United States Workforce. Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000
P F I Z E R F A C T S Obesity in the United States Workforce Findings from the National Health and Nutrition Examination Surveys (NHANES) III and 1999-2000 p p Obesity in The United States Workforce One
More informationClinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D.
Clinical Research on Lifestyle Interventions to Treat Obesity and Asthma in Primary Care Jun Ma, M.D., Ph.D. Associate Investigator Palo Alto Medical Foundation Research Institute Consulting Assistant
More informationPublished Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005
Published Quarterly Mangalore, South India ISSN 0972-5997 Volume 4, Issue 1; January-March 2005 Original Article Genetic Association Between Insulin Resistance And Total Cholesterol In Type 2 Diabetes
More informationYour healthcare provider has ordered a Boston Heart Cardiac Risk Assessment
Your healthcare provider has ordered a Boston Heart Cardiac Risk Assessment What does that mean for you? Your healthcare provider has determined that you may be at risk for cardiovascular disease (CVD).
More informationINSULIN RESISTANCE AND COMPENSATORY HYPERINSULINEMIA: THE LINCHPIN BETWEEN OBESITY AND CARDIOVASCULAR DISEASE
May 2008 (Vol. 1, Issue 2, pages 4-10) INSULIN RESISTANCE AND COMPENSATORY HYPERINSULINEMIA: THE LINCHPIN BETWEEN OBESITY AND CARDIOVASCULAR DISEASE By Gerald M. Reaven, MD, Division of Cardiovascular
More informationEffects of Conventional or Lower Doses of Hormone Replacement Therapy in Postmenopausal Women
Effects of Conventional or Lower Doses of Hormone Replacement Therapy in Postmenopausal Women Kwang Kon Koh, Mi-Seung Shin, Ichiro Sakuma, Jeong Yeal Ahn, Dong Kyu Jin, Hyung Sik Kim, Dae Sung Kim, Seung
More informationOBESITY IS COMMONLY associated with insulin resistance
0021-972X/01/$03.00/0 Vol. 86, No. 5 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 2001 by The Endocrine Society Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close
More informationDISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD
STROKE AND HEART DISEASE IS THERE A LINK BEYOND RISK FACTORS? D AN IE L T. L AC K L AN D DISCLOSURES Member of NHLBI Risk Assessment Workgroup RISK ASSESSMENT Count major risk factors For patients with
More information1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME
1. PATHOPHYSIOLOGY OF METABOLIC SYNDROME Izet Aganović, Tina Dušek Department of Internal Medicine, Division of Endocrinology, University Hospital Center Zagreb, Croatia 1 Introduction The metabolic syndrome
More informationPrevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012
Prevention of and the Screening for Diabetes Part I Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner January 19, 2012 In 2002, SETMA began a relationship with Joslin Diabetes
More informationListen to your heart: Good Cardiovascular Health for Life
Listen to your heart: Good Cardiovascular Health for Life Luis R. Castellanos MD, MPH Assistant Clinical Professor of Medicine University of California San Diego School of Medicine Sulpizio Family Cardiovascular
More informationPrimary Care Management of Women with Hyperlipidemia. Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing
Primary Care Management of Women with Hyperlipidemia Julie Marfell, DNP, BC, FNP, Chairperson, Department of Family Nursing Objectives: Define dyslipidemia in women Discuss the investigation process leading
More informationCardiovascular Disease Risk Factors Part XII Insulin Resistance By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005
Cardiovascular Disease Risk Factors Part XII By James L. Holly, MD Your Life Your Health The Examiner September 15, 2005 As we approach the end of our extended series on cardiovascular disease risk factors,
More informationPsoriasis Co-morbidities: Changing Clinical Practice. Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology. Psoriatic Arthritis
Psoriasis Co-morbidities: Changing Clinical Practice Theresa Schroeder Devere, MD Assistant Professor, OHSU Dermatology Psoriatic Arthritis Psoriatic Arthritis! 11-31% of patients with psoriasis have psoriatic
More informationDiabetes and Stroke. Understanding the connection between diabetes and the increased risk of stroke
Diabetes and Stroke Understanding the connection between diabetes and the increased risk of stroke Make the Connection Almost 26 million people in the U.S. roughly 8 percent of the population have diabetes.
More informationTYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION. Robert Dobbins, M.D. Ph.D.
TYPE 2 DIABETES MELLITUS: NEW HOPE FOR PREVENTION Robert Dobbins, M.D. Ph.D. Learning Objectives Recognize current trends in the prevalence of type 2 diabetes. Learn differences between type 1 and type
More informationTHE THIRD REPORT OF THE EXpert
SPECIAL COMMUNICATION Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
More informationSponsor. Novartis Generic Drug Name. Vildagliptin. Therapeutic Area of Trial. Type 2 diabetes. Approved Indication. Investigational.
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Investigational Study Number CLAF237A2386 Title A single-center,
More informationHistorically, diabetes has been considered
THE LINK BETWEEN TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE* Thomas G. Bartol, NP, CDE ABSTRACT The link between type 2 diabetes and cardiovascular disease has been amply demonstrated in numerous studies.
More informationCan Common Blood Pressure Medications Cause Diabetes?
Can Common Blood Pressure Medications Cause Diabetes? By Nieske Zabriskie, ND High blood pressure, or hypertension, is a major risk factor for cardiovascular disease. In the United States, approximately
More informationManagement of Lipids in 2015: Just Give them a Statin?
Management of Lipids in 2015: Just Give them a Statin? James H. Stein, M.D. Division of Cardiovascular Medicine University of Wisconsin School of Medicine and Public Health Stone NJ, et al. Circulation
More informationTreatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).
Complete Summary GUIDELINE TITLE (1)Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment
More informationDCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study
DCCT and EDIC: The Diabetes Control and Complications Trial and Follow-up Study National Diabetes Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What
More informationThe WHI 12 Years Later: What Have We Learned about Postmenopausal HRT?
AACE 23 rd Annual Scientific and Clinical Congress (2014) Syllabus Materials: The WHI 12 Years Later: What Have We Learned about Postmenopausal HRT? JoAnn E. Manson, MD, DrPH, FACP, FACE Chief, Division
More informationHYPERCHOLESTEROLAEMIA STATIN AND BEYOND
HYPERCHOLESTEROLAEMIA STATIN AND BEYOND Andrea Luk Division of Endocrinology Department of Medicine & Therapeutics The Chinese University of Hong Kong HA Convention 4 May 2016 Statins reduce CVD and all-cause
More informationSupplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works?
Supplements, Vitamin D, Omega-3 Fatty Acids, and Co-Enzyme Q10: What Really Works? DAVID P. GOWMAN, D.O. S E C T I O N CHIEF, CARDIOLOGY P R O G R A M D I R E C T O R, CARDIOLOGY F E L L O W S H I P B
More informationGuidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes
Guidance for Industry Diabetes Mellitus Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes U.S. Department of Health and Human Services Food and Drug Administration Center
More informationIsagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc.
Isagenix Clinical Research Summary Suk Cho, Ph.D., Eric Gumpricht, Ph.D., David Despain, M.Sc. UIC study finds subjects on Isagenix products lost more body fat, lost more visceral fat, showed greater adherence,
More informationGuideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. Learn and Live SM. ACCF/AHA Pocket Guideline
Learn and Live SM ACCF/AHA Pocket Guideline Based on the 2010 ACCF/AHA Guideline Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults November 2010 Guideline for Assessment of Cardiovascular
More informationThe National Cholesterol Education Program s Adult
NHLBI/AHA Conference Proceedings Definition of Metabolic Syndrome Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition
More informationPlasma Testosterone Level in Male Patients with Metabolic Syndrome
Med. J. Cairo Univ., Vol. 77, No. 1, June: 351-357, 2009 www.medicaljournalofcairouniversity.com Plasma Testosterone Level in Male Patients with Metabolic Syndrome NASHWA EL-SARRAF, M.D. and AMR EL-HADIDY,
More informationDegree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women
Available online at www.sciencedirect.com Metabolism Clinical and Experimental 58 (2009) 1096 1101 www.metabolismjournal.com Degree of weight loss required to improve adipokine concentrations and decrease
More informationStatins for Hyperlipidemia (High Cholesterol)
Statins for Hyperlipidemia (High Cholesterol) Examples of statin drugs Brand Name Mevacor Pravachol Zocor Lescol, Lescol XL Lipitor Crestor Chemical Name lovastatin pravastatin sodium simvastatin fluvastatin
More informationEvaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease
Journal homepage: http://www.journalijar.com INTERNATIONAL JOURNAL OF ADVANCED RESEARCH RESEARCH ARTICLE Evaluation of Non-HDL-Cholesterol/HDL-cholesterol ratio as a predictor of coronary artery disease
More informationINSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME
1 University of Papua New Guinea School of Medicine and Health Sciences Division of Basic Medical Sciences Discipline of Biochemistry and Molecular Biology PBL SEMINAR INSULIN RESISTANCE, POLYCYSTIC OVARIAN
More informationSerum testosterone and short-term mortality in men with acute myocardial infarction
ORIGINAL ARTICLE Cardiology Journal 2010, Vol. 17, No. 3, pp. 249 253 Copyright 2010 Via Medica ISSN 1897 5593 Serum testosterone and short-term mortality in men with acute myocardial infarction Constantin
More informationTestosterone and Heart Disease
Testosterone and Heart Disease By Pamela W. Smith, M.D., MPH, MS Introduction Two recent trials suggest that testosterone replacement therapy may increase the risk of heart disease and/or stroke. 1, 2
More informationOmega-3 Fatty Acid Products
Omega-3 Fatty Acid Products Policy Number: 5.01.563 Last Review: 7/2016 Origination: 6/2014 Next Review: 7/2017 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for the
More informationDiabetes mellitus. Lecture Outline
Diabetes mellitus Lecture Outline I. Diagnosis II. Epidemiology III. Causes of diabetes IV. Health Problems and Diabetes V. Treating Diabetes VI. Physical activity and diabetes 1 Diabetes Disorder characterized
More informationWelchol (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
More informationMargarines and Heart Disease. Do they protect?
Margarines and Heart Disease Do they protect? Heart disease Several studies, including our own link margarine consumption with heart disease. Probably related to trans fatty acids elevate LDL cholesterol
More informationYOUR GUIDE TO. Managing and Understanding Your Cholesterol Levels
YOUR GUIDE TO Managing and Understanding Your Cholesterol Levels Our goal at the Mercy Health Heart Institute is to help you be well. Our experienced team includes cardiologists, cardiovascular surgeons,
More informationClinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular Disease A Retrospective Single Center Experience
International Scholarly Research Network ISRN Cardiology Volume 2012, Article ID 874706, 5 pages doi:10.5402/2012/874706 Clinical Study The Sweet Spot: Continued Search for the Glycemic Threshold for Macrovascular
More informationThe Effect of Resistance Training on Adiponectin and Insulin Resistance Index in Over Weight College,s Students Girl
2011 International Conference on Environmental, Biomedical and Biotechnology IPCBEE vol.16 (2011) (2011)IACSIT Press, Singapoore The Effect of Resistance Training on Adiponectin and Insulin Resistance
More informationEffect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus
The American Journal of Medicine (2007) Vol 120 (3A), S12 S18 Effect of Insulin Resistance, Dyslipidemia, and Intra-abdominal Adiposity on the Development of Cardiovascular Disease and Diabetes Mellitus
More informationMen Sexual Dysfunction Associated with Obesity and Metabolic Syndrome
Men Sexual Dysfunction Associated with Obesity and Metabolic Syndrome By Aly A. Abbassy, MD, FACE Professor of Medicine (Endocrinology) Alexandria University My Talk will include: 1-Types of Men sexual
More informationDEVELOPING WHEY-BASED INNOVATIVE BIOACTIVE INGREDIENTS. Éric Simard, Ph.D. Vice-President, Operations BiolActis, Canada
DEVELOPING WHEY-BASED INNOVATIVE BIOACTIVE INGREDIENTS Éric Simard, Ph.D. Vice-President, Operations BiolActis, Canada Modus Operandi BiolActis commercializes innovative and clinically proven Whey-Based
More informationESCMID Online Lecture Library. by author
Do statins improve outcomes of patients with sepsis and pneumonia? Jordi Carratalà Department of Infectious Diseases Statins for sepsis & community-acquired pneumonia Sepsis and CAP are major healthcare
More informationChristina L. Aquilante, Pharm.D.; and Joseph P. Vande Griend, Pharm.D., BCPS
Metabolic Syndrome Christina L. Aquilante, Pharm.D.; and Joseph P. Vande Griend, Pharm.D., BCPS Reviewed by Tracey H. Taveira, Pharm.D., CDOE; Judy W.M. Cheng, Pharm.D., MPH, FCCP, BCPS, (AQ Cardiology);
More informationWhy is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus?
Why is HDL Cholesterol Low in People with Insulin Resistance and Type 2 Diabetes Mellitus? Henry Ginsberg, MD Columbia University College of Physicians and Surgeons Henry Ginsberg: Disclosures Research
More informationBRIEF OBSERVATION. California Los Angeles School of Medicine, Los Angeles.
BRIEF OBSERVATION Effects of Intense Exercise and Moderate Caloric Restriction on Cardiovascular Risk Factors and Inflammation Naser Ahmadi, MD, a,b Shervin Eshaghian, MD, a Robert Huizenga, MD, a Kira
More informationPioglitazone Restores Endothelial Function in Patients with Type 2 Diabetes Treated with Insulin ABSTRACT
METABOLIC SYNDROME AND RELATED DISORDERS Volume 4, Number 3, 2006 Mary Ann Liebert, Inc. Pp. 179 184 Pioglitazone Restores Endothelial Function in Patients with Type 2 Diabetes Treated with Insulin SUNIL
More informationOverview of Diabetes Management. By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health
Overview of Diabetes Management By Cindy Daversa, M.S.,R.D.,C.D.E. UCI Health Objectives: Describe the pathophysiology of diabetes. From a multiorgan systems viewpoint. Identify the types of diabetes.
More informationRheumatoid Factor is a Strong Risk Factor for Coronary Artery Disease in Men with Metabolic Syndrome
Original Article RF is a Risk Factor for CAD in MS Men Acta Cardiol Sin 2010;26:89 93 Coronary Heart Disease Rheumatoid Factor is a Strong Risk Factor for Coronary Artery Disease in Men with Metabolic
More informationMale Health. The three major issues are: Cardiovascular Health Prostate Health Fertility & Sexual Performance
Male Health Do Men Value Their Health? The ancient Greek physician Hippocrates once said, A wise man ought to realise that his health is his most valuable possession. It is believed that Hippocrates lived
More informationCoxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation
Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation Steffen Gay Arthritis linked to cardiovascular disease CV Death Osteoarthritis CHF Rheumatoid
More informationHow To Know If Coffee Increases Type 2 Diabetes Risk
help in type 2 diabetes risk reduction? 14th November 2013 Contents Page 1 Introduction 2 2 Epidemiological evidence 3 3 Clinical intervention trials 4 4 Clinical parameters 5 5 Underlying mechanisms 6
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationCardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better
Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better Marian Taylor, M.D. Medical University of South Carolina Director, Cardiac Rehabilitation I have no disclosures.
More informationTreating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group. Learning Objectives. Background. CAPA 2015 Annual Conference
Treating Patients with PRE-DIABETES David Doriguzzi, PA-C First Valley Medical Group Learning Objectives To accurately make the diagnosis of pre-diabetes/metabolic syndrome To understand the prevalence
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationGuidelines for the management of hypertension in patients with diabetes mellitus
Guidelines for the management of hypertension in patients with diabetes mellitus Quick reference guide In the Eastern Mediterranean Region, there has been a rapid increase in the incidence of diabetes
More informationHôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires
Hôpitaux Universitaires de Genève Lipides, métabolisme des hydrates de carbonne et maladies cardio-vasculaires Prof. J. Philippe Effect of estrogens on glucose metabolism : Fasting Glucose, HbA1c and C-Peptide
More informationCoronary heart disease (CHD) has an enormous
GLOBAL RISK ASSESSMENT IN CARDIOVASCULAR DISEASE * Steven P. Schulman, MD ABSTRACT Cardiovascular disease is the leading cause of mortality in the United States. Importantly, atherosclerosis begins at
More informationCholesterol and Triglycerides What You Should Know
Cholesterol and Triglycerides What You Should Know Michael T. McDermott MD Professor of Medicine Endocrinology Practice Director Division of Endocrinology, Metabolism and Diabetes University of Colorado
More informationTHE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES. Key Points
December 2008 (Vol. 1, Issue 3, pages 36-40) THE ENDOCANNABINOID SYSTEM AS A THERAPEUTIC TARGET FOR LIVER DISEASES By Sophie Lotersztajn, PhD, Ariane Mallat, MD, PhD Inserm U841, Hôpital Henri Mondor,
More informationCME Test for AMDA Clinical Practice Guideline. Diabetes Mellitus
CME Test for AMDA Clinical Practice Guideline Diabetes Mellitus Part I: 1. Which one of the following statements about type 2 diabetes is not accurate? a. Diabetics are at increased risk of experiencing
More informationCurriculum Vitae Eric S. Miguelino, M.D. Staff Toxicologist, Department of Public Health, Food and Drug Branch, State of California
updated 02/10 Curriculum Vitae Eric S. Miguelino, M.D. Staff Toxicologist, Department of Public Health, Food and Drug Branch, Office Address: Department of Public Health Food and Drug Branch Medical Device
More informationPerioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time
Perioperative management of Dual Antiplatelet therapy post drug eluting stent-changing time Robert Chilton DO, FACOI, FACC, FAHA Professor of Medicine University of Texas Health Science Center Director
More informationType 2 Diabetes Mellitus and Insulin resistance syndrome in Children
Type 2 Diabetes Mellitus and Insulin resistance syndrome in Children Anil R Kumar MD Pediatric Endocrinology MCV/VCU, Richmond VA Introduction Type 2 diabetes mellitus (T2 DM) has increased in children
More information